Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the transition period from __________to__________ Commission File Number: 001-39801 XOMA Royalty Corporation (Exact name of Registrant as specified in its charter) Delaware 52-2154066 ...

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milesto ...

XOMA Royalty Corporation (NASDAQ: XOMA ) is a biotechnology royalty aggregator that obtains milestone and royalty rights from investigational and commercial drugs. XOMA's business model is to provide nondilutive funding to biotech companies, allowing them to fund their research without My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens ...

XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, representing a turnover rate of 0.03% and a price fluctuation amplitude of 3.79%. Financial reports indicate that XOMA achieved a revenue of $11.09 million, net profit of $15.99 million, and earnings per share of $0.88. The gross profit stood at $11.08 million, with a price-to-earnings ratio of -11.85. Within the indust ...

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cu ...

Core Insights - XOMA Royalty Corporation will participate in two upcoming investor conferences in September 2024, presenting corporate overviews at both events [1][2]. Group 1: Upcoming Conferences - XOMA will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York, with a presentation scheduled for September 9 at 9:00 AM ET [1]. - The company will also present at the 2024 Cantor Global Healthcare Conference from September 17-19, 2024, in New York, with a presentation on September 17 at 2:30 PM ET [1]. Group 2: Access to Presentations - Presentations can be accessed via the investor relations section of XOMA's website, and replays will be available for 90 days post-event [2]. Group 3: Company Overview - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical or biotech companies [3]. - The company provides non-dilutive, non-recourse funding to sellers, enabling them to advance their drug candidates or for general corporate purposes [3]. - XOMA has a growing portfolio of assets, defined as rights to receive potential future economics from therapeutic candidates [3].

XOMA Royalty (XOMA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -7.69%. A quarter ago, it was expected that this drug developer would post a loss of $0.71 per share when it actually produced a loss of $0.86, delivering a surprise of -21.13%. Over the last four quarters, the company has n ...

Exhibit 99.1 XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel Phase 3 assets, from Daré Bioscience Completed the acquisition of Kinnate Pharmaceuticals, adding several potent ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ | --- | --- | |-------------------------------------------------------------------------------------------------|-------------------------------- ...

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Key Second Quarter Events Partner Event The U.S. Food and Drug Administration (FDA) approved Day One's OJEMDA™ (tovorafenib) for use in patients with pediatric low-grade glioma (pLGG). XOMA Royalty earned a $9.0 million milestone upon the approval and recorded $0.4 million in income resulting from OJEMDA™ sales in the second quarter of 2024. In addition, XOMA Royalty received an ...